Shilpa Pharma Lifesciences received CEP from EDQM for API, Teriflunomide
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
Earlier initiation with Kesimpta resulted in a more than three-fold increased likelihood of maintaining NEDA-3 throughout the study
Subscribe To Our Newsletter & Stay Updated